Perioperative Cemiplimab Demonstrates Continued Efficacy in Stage II to IV CSCC

Perioperative treatment with cemiplimab continued to produce signs of efficacy in patients with resectable stage II to IV cutaneous squamous cell carcinoma.

Related Keywords

Spain ,Texas ,United States ,Houston ,Madrid ,Neild Gross , ,University Of Texas Md Anderson Cancer Center ,Lancet Oncology ,Cancer Center ,Cemiplimab ,Cutaneous Squamous Cell Carcinoma ,Mcscc ,Esmo Congress ,